Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Colonic Neoplasms 1Advanced Glioblastoma 1

Interventions

Cyclophosphamide 42Cytarabine 25fludarabine phosphate 24Dexamethasone 23Methotrexate 22fludarabine 21Peripheral Blood Stem Cell Transplantation 21Vincristine 16Filgrastim 16venetoclax 14Etoposide 13Rituximab 12Mycophenolic Acid 12Whole-Body Irradiation 11Cyclosporine 10Clofarabine 10Calcium Dobesilate 10blinatumomab 9Tacrolimus 9pegaspargase 8Busulfan 8Bortezomib 8Alemtuzumab 8Mitoxantrone 7Melphalan 7Leucovorin 7Immunotherapy, Adoptive 7nilotinib 6Mesna 6Mercaptopurine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × TIC10 compound × Clear all
NCT02392572 2026-04-14

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
120 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡